Abstract
Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.
Keywords: Angiogenesis, renal cell carcinoma, VHL, VEGF, sorafenib, sumitinib, bevacizumab, temsirolimus, mTOR, angiopoietins
Recent Patents on Anti-Cancer Drug Discovery
Title: Anti-Angiogenic Therapy in Renal Cell Carcinoma
Volume: 5 Issue: 1
Author(s): Shree G. Sharma, Sudip Nanda and Santo Longo
Affiliation:
Keywords: Angiogenesis, renal cell carcinoma, VHL, VEGF, sorafenib, sumitinib, bevacizumab, temsirolimus, mTOR, angiopoietins
Abstract: Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.
Export Options
About this article
Cite this article as:
Sharma G. Shree, Nanda Sudip and Longo Santo, Anti-Angiogenic Therapy in Renal Cell Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702181
DOI https://dx.doi.org/10.2174/157489210789702181 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epidermal Growth Factor Receptors: A Functional Perspective
Current Radiopharmaceuticals Sirtuins: Nodes Connecting Aging, Metabolism and Tumorigenesis
Current Pharmaceutical Design Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy The Role of Androgen Under Normal and Pathological Conditions in Sebaceous Glands: The Possibility of Target Therapy
Current Molecular Pharmacology Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Can Colorectal Cancer be Prevented or Treated by Oral Hormone Replacement Therapy?
Current Molecular Pharmacology Vascular Targeting: A New Antitumor Activity
Drug Design Reviews - Online (Discontinued) Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Automated Detection of Breast Tumor in Different Imaging Modalities: A Review
Current Medical Imaging 1,5-Diaryl-3-oxo-1,4-pentadienes: A Case for Antineoplastics with Multiple Targets
Current Medicinal Chemistry New Molecules and Strategies in the Field of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Fractal Analysis of Epithelial-Connective Tissue Interface in Basal Cell Carcinoma of the Skin
Current Bioinformatics Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Indolealkylamines from Toad Vertebrates and Sea Invertebrates - Their Identification and Potential Activities on the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Highly Active Antiretroviral Therapy and Cardiovascular Complications in HIV-Infected Patients
Current Pharmaceutical Design